Results showed that IMFINZI-based treatment before and after surgery significantly increased the time patients live without recurrence or progression events WILMINGTON, Del.–(BUSINESS WIRE)–Positive high-level results from a planned interim analysis of the AEGEAN Phase III, placebo-controlled trial showed that treatment with AstraZeneca’s IMFINZI® (durvalumab) in combination with neoadjuvant chemotherapy before surgery and as adjuvant monotherapy … [Read more…]

HOUSTON–(BUSINESS WIRE)–Coya Therapeutics, Inc. (NASDAQ: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing multiple therapeutic platforms intended to enhance Treg function, including biologics and cell therapies, today announced it will host a conference call to present clinical data of Coya’s proprietary investigational biologic combination, COYA 302, in patients with Amyotrophic Lateral Sclerosis (ALS), … [Read more…]

REDWOOD CITY, Calif. & BOSTON–(BUSINESS WIRE)–Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer, today announced that Chen Schor, President and Chief Executive Officer, and Nick Harvey, Chief Financial Officer, will participate in the 2023 Jefferies Biotech on the Bay Summit being held … [Read more…]

Robin Leopold, EVP and Head of Human Resources at JPMorgan Chase, Joins LetsGetChecked Board of Directors NEW YORK–(BUSINESS WIRE)–LetsGetChecked, a global healthcare solutions company, announced today the appointment of Robin Leopold, Executive Vice President and Head of Human Resources at JPMorgan Chase, and a member of the company’s Operating Committee, to its Board of Directors. … [Read more…]

Revenue grew 3.5x YoY, to $1.11 billion, exceeding guidance Cost of Care Delivery (COCD) Margin in the U.K. already profitable1, with U.S. Clinical services also expecting COCD profitability in early 2023 Key U.S. VBC contracts delivered profitable Medical Margins2 in their first year Monthly Adjusted EBITDA of $(16.3) million for Q4 2022 beating guidance of … [Read more…]

DUBLIN–(BUSINESS WIRE)–The “United States Specialty Generics Market: Industry Trends, Share, Size, Growth, Opportunity and Forecast 2022-2027” report has been added to ResearchAndMarkets.com’s offering. The United States specialty generics market size reached US$ 23.6 Billion in 2021. Looking forward, the publisher expects the market to reach US$ 43.1 Billion by 2027, exhibiting a CAGR of 10.56% … [Read more…]

Principal investigator Professor Peter Pickkers to present data at ISICEM on March 21st in Brussels and at the AKI & CRRT conference on March 29th in San Diego A significant reduction in major adverse kidney events by day 90 and no difference in 28-day all-cause mortality was observed after review of the data from all … [Read more…]

DUBLIN–(BUSINESS WIRE)–The “Global Markets for Microbiology Technology, Equipment and Consumables” report has been added to ResearchAndMarkets.com’s offering. Growth in the market has historically resulted from increased health care expenditure, emerging market growth, rapid technological advances, rapid growth in the aging population, and the emergence of novel pathogenic infections. Factors that have negatively affected the market … [Read more…]

DUBLIN–(BUSINESS WIRE)–The “Cutaneous T-Cell Lymphoma – Pipeline Insight, 2022” clinical trials has been added to ResearchAndMarkets.com’s offering. This “Cutaneous T-Cell Lymphoma – Pipeline Insight, 2022” report provides comprehensive insights about 25+ companies and 27+ pipeline drugs in Cutaneous T-Cell Lymphoma pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It … [Read more…]

SINGAPORE–(BUSINESS WIRE)–#PAUF–Prestige Biopharma Limited, a Singapore-based biopharmaceutical company, has developed a first-in-class diagnostic kit for pancreatic cancer. Pancreatic cancer is a characteristically aggressive tumor, with an extremely poor prognosis, as shown by a 1-year survival rate of 10 to 23%, and an estimated 5-year survival rate of less than 9%1. The low survival rates associated … [Read more…]